Ka Lip Chew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ka Lip Chew has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Jeanette Woon Pei Teo
Department of Laboratory Medicine, National University Hospital, Singapore, Singapore
29 shared publications - Sophie Octavia
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia
10 shared publications Roland Jureen
Department of Laboratory Medicine, National University Hospital, Singapore
8 shared publicationsSophie Octavia
Environmental Health Institute, National Environment Agency, Singapore
8 shared publications- Jinghao Nicholas Ngiam
Division of Infectious Diseases, Department of Medicine National University Hospital, National University Health System Singapore Singapore
7 shared publications - Matthew Chung Yi Koh
Division of Infectious Diseases, Department of Medicine, National University Health System, Singapore, Singapore
6 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clinical presentation and outcomes in non-maltophilia Stenotrophomonas spp. bloodstream infections
Stenotrophomonas maltophilia complex is an important nosocomial cause of bacteraemia. The complex comprises multiple species, but their relative clinical and genomic significance remains unclear. We examined clinical and genomic differences between S. maltophilia and non- S. maltophilia species to better understand their virulence and implications for patient care. Hospitalized adult patients (≥ 21 years) between January 2022 and June 2024 with Stenotrophomonas species bacteraemia were examined. Clinical data were extracted from electronic medical records. Whole-genome sequencing was performed on all isolates, with species assignment confirmed by average nucleotide identity. S. maltophilia and non- S. maltophilia species were compared. Fifty-three S. maltophilia complex isolates were identified, of which 45 had clinical data. S. maltophilia predominated (n = 32), followed by S. pavanii (n = 7), S. sepilia (n = 4), S. muris (n = 1), and S. geniculata (n = 1). S. maltophilia isolates formed multiple clades with diverse sequence types, consistent with both clonal expansion and ongoing diversification. Virulence genes, including stmPr , smoR , and iron acquisition-associated genes were conserved across S. maltophilia lineages, but stmPr1 was less frequently observed in non- S. maltophilia . Most infections were line-related. Pneumonia-associated bacteraemia appeared more frequently among with S. maltophilia infections. Polymicrobial bacteraemia appeared more commonly in non- S. maltophilia infections. Mortality was similar between groups, but recurrence of infection within one year occurred only in S. maltophilia . Compared with non- S. maltophilia, S. maltophilia appeared to be associated with pneumonia and recurrent bacteraemia episodes, although mortality was similar. These exploratory findings suggest potential differences within the complex, but require validation in larger studies.
- 6 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClinical presentation and outcomes in non-maltophilia Stenotrophomonas spp. bloodstream infections
Stenotrophomonas maltophilia complex is an important nosocomial cause of bacteraemia. The complex comprises multiple species, but their relative clinical and genomic significance remains unclear. We examined clinical and genomic differences between S. maltophilia and non- S. maltophilia species to better understand their virulence and implications for patient care. Hospitalized adult patients (≥ 21 years) between January 2022 and June 2024 with Stenotrophomonas species bacteraemia were examined. Clinical data were extracted from electronic medical records. Whole-genome sequencing was performed on all isolates, with species assignment confirmed by average nucleotide identity. S. maltophilia and non- S. maltophilia species were compared. Fifty-three S. maltophilia complex isolates were identified, of which 45 had clinical data. S. maltophilia predominated (n = 32), followed by S. pavanii (n = 7), S. sepilia (n = 4), S. muris (n = 1), and S. geniculata (n = 1). S. maltophilia isolates formed multiple clades with diverse sequence types, consistent with both clonal expansion and ongoing diversification. Virulence genes, including stmPr , smoR , and iron acquisition-associated genes were conserved across S. maltophilia lineages, but stmPr1 was less frequently observed in non- S. maltophilia . Most infections were line-related. Pneumonia-associated bacteraemia appeared more frequently among with S. maltophilia infections. Polymicrobial bacteraemia appeared more commonly in non- S. maltophilia infections. Mortality was similar between groups, but recurrence of infection within one year occurred only in S. maltophilia . Compared with non- S. maltophilia, S. maltophilia appeared to be associated with pneumonia and recurrent bacteraemia episodes, although mortality was similar. These exploratory findings suggest potential differences within the complex, but require validation in larger studies.
- Open Access
- 9 April 2026
- Published by Springer Nature in Gut Pathogens
- Vol. 18 (1)
Recurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts
Objectives: Campylobacter jejuni is a leading cause of bacterial gastroenteritis but rarely causes bacteraemia, except in immunocompromised hosts. Carbapenem resistance in C. jejuni remains uncommon, and the clinical evolution of resistance during infection has not been well described. Methods: We report a case series of three immunocompromised adults with recurrent C. jejuni bacteraemia at a tertiary hospital in Singapore between 2024 and 2025. Results: All three patients had underlying haematologic or autoimmune disorders associated with hypogammaglobulinaemia. Each experienced multiple episodes of C. jejuni bacteraemia despite prolonged carbapenem therapy, with isolates showing stepwise increases in meropenem minimum inhibitory concentrations (MICs) from ≤ 0.05 mg/L to as high as 16 mg/L. No abscesses or drainable foci were identified radiologically. Two patients received regular intravenous immunoglobulin (IVIG) replacement after low serum IgG levels were detected. In all cases, recurrences ceased after introduction of eravacycline therapy, with or without concurrent oral gentamicin, in combination with IVIG support. One patient later died of progression of underlying lymphoma. Conclusions: This series demonstrates the potential for acquired carbapenem resistance to develop in C. jejuni during recurrent bacteraemia in immunocompromised hosts. Eravacycline, alongside immunoglobulin replacement, may represent a viable therapeutic option in such refractory infections.
- 9 April 2026
- Published by Springer Nature in Gut Pathogens
- Vol. 18 (1)
Open AccessRecurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts
Objectives: Campylobacter jejuni is a leading cause of bacterial gastroenteritis but rarely causes bacteraemia, except in immunocompromised hosts. Carbapenem resistance in C. jejuni remains uncommon, and the clinical evolution of resistance during infection has not been well described. Methods: We report a case series of three immunocompromised adults with recurrent C. jejuni bacteraemia at a tertiary hospital in Singapore between 2024 and 2025. Results: All three patients had underlying haematologic or autoimmune disorders associated with hypogammaglobulinaemia. Each experienced multiple episodes of C. jejuni bacteraemia despite prolonged carbapenem therapy, with isolates showing stepwise increases in meropenem minimum inhibitory concentrations (MICs) from ≤ 0.05 mg/L to as high as 16 mg/L. No abscesses or drainable foci were identified radiologically. Two patients received regular intravenous immunoglobulin (IVIG) replacement after low serum IgG levels were detected. In all cases, recurrences ceased after introduction of eravacycline therapy, with or without concurrent oral gentamicin, in combination with IVIG support. One patient later died of progression of underlying lymphoma. Conclusions: This series demonstrates the potential for acquired carbapenem resistance to develop in C. jejuni during recurrent bacteraemia in immunocompromised hosts. Eravacycline, alongside immunoglobulin replacement, may represent a viable therapeutic option in such refractory infections.
- Open Access
- 10 February 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Evaluating a Flexible Workflow for Candida auris Surveillance on the AltoStar Automation System AM16 with Commercial and In-House Real-Time PCR Assays
Chun Kiat Lee, M.S., Janet Weng Sze Cheng, B.S., Nur Atiqah Liyana, B.S., Dilys Shi Ning Lau, B.S., Kelvin Kyaw Lin, M.T., Tim Hon Man Chan, Ph.D., Ka Lip Chew, M.B.B.S., and Jeanette Woon Pei Teo, Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0574
- 10 February 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessEvaluating a Flexible Workflow for Candida auris Surveillance on the AltoStar Automation System AM16 with Commercial and In-House Real-Time PCR Assays
Chun Kiat Lee, M.S., Janet Weng Sze Cheng, B.S., Nur Atiqah Liyana, B.S., Dilys Shi Ning Lau, B.S., Kelvin Kyaw Lin, M.T., Tim Hon Man Chan, Ph.D., Ka Lip Chew, M.B.B.S., and Jeanette Woon Pei Teo, Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0574
- Open Access
- 1 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0027325
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing Enterobacterales bacteremia
International guidance recommends ceftazidime-avibactam for OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE) infections. However, OXA-48-CPE lacking extended spectrum and AmpC β-lactamases may remain susceptible to third-generation cephalosporins (3GC), potentially allowing treatment without avibactam. OXA-23 also has variable hydrolytic activity against 3GC. This study reviewed the outcomes of OXA-CPE bloodstream infections treated based on phenotypic susceptibility testing. A retrospective review of OXA-48-CPE and OXA-23-CPE bloodstream infections was conducted from February 2022 to July 2024. Data on antimicrobial susceptibility, patient background, infection source, treatments, and outcomes were analyzed. Whole-genome sequencing (WGS) determined the presence of β-lactamase genes in available isolates. Ten bloodstream infection episodes occurred in nine patients (eight OXA-48-like Escherichia coli [ n = 4], Klebsiella pneumoniae [ n = 4], and one OXA-23-CPE Proteus mirabilis ), with a urinary source in 44.4% ( n = 4). Of the isolates, 5/9 (55.5%) were 3GC-susceptible. WGS did not identify any extended-spectrum β-lactamases in these isolates. Three 3GC-susceptible cases (two OXA-48 and one OXA-23) were successfully treated with ceftriaxone. Among the 3GC-resistant cases, two were treated with ceftazidime-avibactam, and two with high-dose meropenem alone or in combination with aztreonam. One recurrence was observed in a case treated with ceftazidime-avibactam. Mortality was low, with one death reported in a patient treated with ceftazidime-avibactam. In this small study, 55.5% of OXA-48-CPE and OXA-23-CPE isolates retained 3GC susceptibility. When used for therapy, 3GC and non-β-lactam antibiotics demonstrated clinical efficacy where antibiotic susceptibility was demonstrated. IMPORTANCE: The Infectious Diseases Society of America guidance document recommends the use of ceftazidime-avibactam for the treatment of OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE). However, this antibiotic is expensive and not always available in some settings. The clinical outcomes of OXA-48-CPE and OXA-23-CPE bloodstream infections when treated with third-generation cephalosporin (3GC) remain unclear. Among 10 episodes in nine patients, we found that five isolates (55.5%) were 3GC-susceptible, with three cases successfully treated with ceftriaxone. Whole-genome sequencing demonstrated the absence of extended-spectrum β-lactamases in the 3GC-susceptible isolates, which aligns with phenotypic 3GC susceptibility. Mortality was low (1/9). Many OXA-48-CPE and OXA-23-CPE infections retain 3GC susceptibility, raising the possibility that these agents may be viable alternatives to ceftazidime-avibactam in select cases.
- 1 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0027325
Open AccessClinical outcomes of phenotype-guided treatment in group D carbapenemase-producing Enterobacterales bacteremia
International guidance recommends ceftazidime-avibactam for OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE) infections. However, OXA-48-CPE lacking extended spectrum and AmpC β-lactamases may remain susceptible to third-generation cephalosporins (3GC), potentially allowing treatment without avibactam. OXA-23 also has variable hydrolytic activity against 3GC. This study reviewed the outcomes of OXA-CPE bloodstream infections treated based on phenotypic susceptibility testing. A retrospective review of OXA-48-CPE and OXA-23-CPE bloodstream infections was conducted from February 2022 to July 2024. Data on antimicrobial susceptibility, patient background, infection source, treatments, and outcomes were analyzed. Whole-genome sequencing (WGS) determined the presence of β-lactamase genes in available isolates. Ten bloodstream infection episodes occurred in nine patients (eight OXA-48-like Escherichia coli [ n = 4], Klebsiella pneumoniae [ n = 4], and one OXA-23-CPE Proteus mirabilis ), with a urinary source in 44.4% ( n = 4). Of the isolates, 5/9 (55.5%) were 3GC-susceptible. WGS did not identify any extended-spectrum β-lactamases in these isolates. Three 3GC-susceptible cases (two OXA-48 and one OXA-23) were successfully treated with ceftriaxone. Among the 3GC-resistant cases, two were treated with ceftazidime-avibactam, and two with high-dose meropenem alone or in combination with aztreonam. One recurrence was observed in a case treated with ceftazidime-avibactam. Mortality was low, with one death reported in a patient treated with ceftazidime-avibactam. In this small study, 55.5% of OXA-48-CPE and OXA-23-CPE isolates retained 3GC susceptibility. When used for therapy, 3GC and non-β-lactam antibiotics demonstrated clinical efficacy where antibiotic susceptibility was demonstrated. IMPORTANCE: The Infectious Diseases Society of America guidance document recommends the use of ceftazidime-avibactam for the treatment of OXA-48-type carbapenemase-producing Enterobacterales (OXA-48-CPE). However, this antibiotic is expensive and not always available in some settings. The clinical outcomes of OXA-48-CPE and OXA-23-CPE bloodstream infections when treated with third-generation cephalosporin (3GC) remain unclear. Among 10 episodes in nine patients, we found that five isolates (55.5%) were 3GC-susceptible, with three cases successfully treated with ceftriaxone. Whole-genome sequencing demonstrated the absence of extended-spectrum β-lactamases in the 3GC-susceptible isolates, which aligns with phenotypic 3GC susceptibility. Mortality was low (1/9). Many OXA-48-CPE and OXA-23-CPE infections retain 3GC susceptibility, raising the possibility that these agents may be viable alternatives to ceftazidime-avibactam in select cases.
- Open Access
- 14 May 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (8) , 102829
Risk factors for mortality and implications on therapy for Stenotrophomonas maltophilia bacteraemia
- 14 May 2025
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 18 (8) , 102829
Open AccessRisk factors for mortality and implications on therapy for Stenotrophomonas maltophilia bacteraemia
- Open Access
- 25 February 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-10
Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024
Bloodstream infections with the non-fermenting Gram-negative organisms Stenotrophomonas maltophilia, Elizabethkingia spp. or Chryseobacterium spp. are observed in nosocomial settings. Comparative description of their clinical presentation, microbiological characteristics, treatment options and outcomes remain to be investigated. We performed a retrospective single-centre analysis of bloodstream infections with the abovementioned three organisms from 1 Jan 2012 to 30 Jun 2024. A total of 349 distinct encounters (from 322 unique patients) were identified with bacteraemia. Stenotrophomonas maltophilia was the commonest (197/349, 56.4%), followed by Elizabethkingia spp. (127/349, 36.4%) and Chryseobacterium spp. (25/349, 7.2%). Prior carbapenem exposure was observed in 59.9% of cases. The majority were related to central lines (58.2%). Most cases were nosocomial in onset (82.5%), and a third were from the intensive care unit (32.1%). A significant proportion of our Stenotrophomonas maltophilia (32.8%) and Chryseobacterium spp. (22.7%) isolates were resistant to levofloxacin, while a majority of the organisms retained susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX) and minocycline. Dual antibiotics were used in a minority of encounters (23/349, 6.6%). Mortality was high across infections with the three organisms, but highest amongst those with Stenotrophomonas maltophilia bacteraemia (41.6%), followed by Elizabethkingia spp. (29.9%) and Chryseobacterium spp. (20.0%). Stenotrophomonas, Elizabethkingia or Chryseobacterium spp bacteraemia was associated with significant mortality. Most cases were nosocomial in acquisition, with prior carbapenem exposure or indwelling central catheters. Fluoroquinolone resistance was common for Stenotrophomonas maltophilia and Chryseobacterium spp., but less prevalent in Elizabethkingia spp., while TMP-SMX and minocycline retained susceptibility. Monitoring these trends would be critical in guiding empiric therapy for these organisms.
- 25 February 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-10
Open AccessClinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024
Bloodstream infections with the non-fermenting Gram-negative organisms Stenotrophomonas maltophilia, Elizabethkingia spp. or Chryseobacterium spp. are observed in nosocomial settings. Comparative description of their clinical presentation, microbiological characteristics, treatment options and outcomes remain to be investigated. We performed a retrospective single-centre analysis of bloodstream infections with the abovementioned three organisms from 1 Jan 2012 to 30 Jun 2024. A total of 349 distinct encounters (from 322 unique patients) were identified with bacteraemia. Stenotrophomonas maltophilia was the commonest (197/349, 56.4%), followed by Elizabethkingia spp. (127/349, 36.4%) and Chryseobacterium spp. (25/349, 7.2%). Prior carbapenem exposure was observed in 59.9% of cases. The majority were related to central lines (58.2%). Most cases were nosocomial in onset (82.5%), and a third were from the intensive care unit (32.1%). A significant proportion of our Stenotrophomonas maltophilia (32.8%) and Chryseobacterium spp. (22.7%) isolates were resistant to levofloxacin, while a majority of the organisms retained susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX) and minocycline. Dual antibiotics were used in a minority of encounters (23/349, 6.6%). Mortality was high across infections with the three organisms, but highest amongst those with Stenotrophomonas maltophilia bacteraemia (41.6%), followed by Elizabethkingia spp. (29.9%) and Chryseobacterium spp. (20.0%). Stenotrophomonas, Elizabethkingia or Chryseobacterium spp bacteraemia was associated with significant mortality. Most cases were nosocomial in acquisition, with prior carbapenem exposure or indwelling central catheters. Fluoroquinolone resistance was common for Stenotrophomonas maltophilia and Chryseobacterium spp., but less prevalent in Elizabethkingia spp., while TMP-SMX and minocycline retained susceptibility. Monitoring these trends would be critical in guiding empiric therapy for these organisms.